AngioDynamics (ANGO) Misses Q3 EPS by 3c, Revenues Miss; Reiterates FY19 EPS/Revenue Mid-Point Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
KeyBanc Upgrades AngioDynamics (ANGO) to Overweight
April 1, 2019 2:06 PM EDTKeyBanc analyst Matthew Mishan upgraded AngioDynamics (NASDAQ: ANGO) from Sector Weight to Overweight with a price target of $33.00.
For an analyst ratings summary and ratings history on AngioDynamics click here. For more ratings news on AngioDynamics click here.
Shares of AngioDynamics closed at $22.86 yesterday.
... MoreAngioDynamics (ANGO) Granted FDA Approval to Begin NanoKnife DIRECT Clinical Study for Treatment of Stage III Pancreatic Cancer
April 1, 2019 6:09 AM EDTAngioDynamics, Inc. (NASDAQ: ANGO) today announced that the United States Food and Drug Administration (FDA) approved the Companys investigational device exemption (IDE) application for its NanoKnife® Irreversible Electroporation Direct IRE Cancer Treatment clinical study (DIRECT).
The DIRECT Study supports a proposed expanded indication for the NanoKnife System in the treatment of Stage III pancreatic cancer. In January 2018, the FDA granted the Companys NanoKnife System a Breakthrough Device Designation under the 21st... More
